CompletedPhase 4

Rasburicase in Tumor Lysis Syndrome

Brazil33 participantsStarted 2006-02

Plain-language summary

The purpose of this study is to determine whether rasburicase is effective and safety in correcting hyperuricemia.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

List of inclusion Criteria: * Acute hyperuricemia patients(uric acid\>8.0 mg/dl) before/during chemotherapy for hematologic malignancies. List of exclusion Criteria: * Hypersensitivity to uricases or any of the excipients. * Known history of hemolytic anemia (G6PD deficiency). The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

What they're measuring

Percentage of patients with uric acid greater-than-normal laboratory levels (hyperuricemia)

Timeframe: 24-48 hours after last dose of rasburicase

Percentage of patients with uric acid greater-than-normal laboratory levels (hyperuricemia)

Timeframe: 28 (+- 3) days after the last dose of rasburicase

Adverse events occurrence

Timeframe: During the study

Trial details

NCT IDNCT00302653

SponsorSanofi

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2006-11

View on ClinicalTrials.gov More Hyperuricemia trials